SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report: January 19, 1994
C. R. Bard, Inc.
(Exact name of registrant as
specified in its charter)
New Jersey 1-6926 22-1454160
(State of Commission File Number IRS Employer
Incorporation) Identification No.
730 Central Avenue, Murray Hill, New Jersey 07974
(Address of principal executive offices) (Zip Code)
(908) 277-8000
(Registrant's telephone number)
Item 5. Other Events
In a news release dated January 19, 1994, C. R. Bard,
Inc. announced that the Food and Drug Administration has determined
that provisions of the Applications Integrity Policy (AIP) should be
applied to its USCI division. The news release, issued by the Company
on January 19, 1994, is incorporated herein by reference, and is
attached hereto as Exhibit 1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
C. R. BARD, INC.
(Registrant)
By: William C. Bopp /s/
William C. Bopp
Senior Vice President
and Chief Financial Officer
Dated: January 19, 1994
Exhibit 1 C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974
News Release
Contact: William C. Bopp
Senior Vice President & CFO
(908) 277-8221
FDA APPLIES AIP TO PENDING APPLICATIONS OF BARD'S USCI DIVISION
MURRAY HILL, NJ - January 19, 1994 - C.R. Bard, Inc. announced
today that the Food and Drug Administration (FDA) has
determined that provisions of the Applications Integrity Policy
(AIP) should be applied to its USCI division.
Consequently, FDA has suspended its review of pre-market
applications that have been submitted by the USCI division and
which are currently pending clearance by the Center for Devices
and Radiological Health. Based upon audits to be conducted by
the company, the FDA will assess the validity of data and
information in USCI's pending pre-market applications.
The company is in continuing discussions in certain related
areas raised by FDA to finally conclude this matter.
C.R. Bard, Inc., headquartered in Murray Hill, NJ, is a leading
multinational developer, manufacturer and marketer of health
care products.
